<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; VIVUS Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/vivus-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(YHOO) Dec 22: Jobless Claims Fall to Record Low &#8211; Economic Highlights</title>
		<link>http://www.stockbloghub.com/2011/12/24/pce-dec-22-jobless-claims-fall-to-record-low-economic-highlights/89109</link>
		<comments>http://www.stockbloghub.com/2011/12/24/pce-dec-22-jobless-claims-fall-to-record-low-economic-highlights/89109#comments</comments>
		<pubDate>Sat, 24 Dec 2011 16:11:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property Management]]></category>
		<category><![CDATA[Micron Technology Inc.]]></category>
		<category><![CDATA[MU]]></category>
		<category><![CDATA[Tibco Software Inc]]></category>
		<category><![CDATA[TIBX]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89109</guid>
		<description><![CDATA[Today’s heavy economic schedule will likely keep the markets focused on domestic matters. The good start provided by the positive initial Jobless Claims report should help give stocks positive momentum today. The GDP revision was on the weak side, but given the stale nature of the data and the relatively no-so-bad internals of report, stocks will most likely take it in the stride. Other key economic reports on deck for a little later release include the Conference Board’s Leading Indicators and final read on the University of Michigan Consumer Sentiment survey for December. Of the pre-market releases, the most favorable reading was on the initial Jobless Claims front, which continued the positive momentum of the last few weeks by falling to the lowest level since April 2008. Contrary to expectations ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/24/pce-dec-22-jobless-claims-fall-to-record-low-economic-highlights/89109/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKAM) Company News for December 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/12/23/akam-company-news-for-december-23-2011-corporate-summary/89194</link>
		<comments>http://www.stockbloghub.com/2011/12/23/akam-company-news-for-december-23-2011-corporate-summary/89194#comments</comments>
		<pubDate>Fri, 23 Dec 2011 18:56:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Internet Information Providers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AKAM]]></category>
		<category><![CDATA[Akamai Technologies Inc.]]></category>
		<category><![CDATA[AM]]></category>
		<category><![CDATA[American Greetings Corporation]]></category>
		<category><![CDATA[BBBY]]></category>
		<category><![CDATA[Bed Bath & Beyond Inc.]]></category>
		<category><![CDATA[Micron Technology Inc.]]></category>
		<category><![CDATA[MU]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WCA Waste Corporation]]></category>
		<category><![CDATA[WCAA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89194</guid>
		<description><![CDATA[•    Micron Technology Inc. (NASDAQ:MU) soared 15.7%, after announcing late on Wednesday that signs suggested that the PC markets’ demand should be higher next year •    Shares of Bed Bath &#38; Beyond Inc. (NASDAQ:BBBY) declined  6.3% after the company said it might report lower-than-expected fourth-quarter earnings results •    Shares of American Greetings Corp. (NYSE:AM) plunged 21.1% after reporting a near 40% drop in its third-quarter profits •    Akamai Technologies, Inc.’s (NASDAQ:AKAM) stocks soared 18.6% after announcing that it would buy Cotendo for $268 million •    Shares of WCA Waste Corporation (NASDAQ:WCAA) soared 30.1% after agreeing to be taken over by Macquairie Infrastructure Partners Inc. for $6.50 a share •    After VIVUS Inc. (NASDAQ:VVUS) spoke of concerns about its diet drug Qnexa, shares of the company slumped 16.6% AKAMAI TECH (AKAM): ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/23/akam-company-news-for-december-23-2011-corporate-summary/89194/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Lifeline for Contrave</title>
		<link>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937</link>
		<comments>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937#comments</comments>
		<pubDate>Sat, 24 Sep 2011 19:00:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83937</guid>
		<description><![CDATA[Orexigen Therapeutics, Inc.&#8216;s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration&#8217;s (FDA) office of new drugs (OND) regarding the development path for its obesity candidate Contrave. Following the OND’s decision, Orexigen decided to resume the development of Contrave. Orexigen is looking to gain approval for Contrave for the treatment of obesity, including weight loss and maintenance of weight loss. The company has a collaboration agreement with Takeda for the development and commercialization of Contrave in the US, Canada and Mexico. Story so far…. In January 2011, Orexigen received a complete response letter (CRL) from the FDA for Contrave. The FDA  expressed concerns regarding the long-term cardiovascular safety profile of Contrave and asked Orexigen to conduct an additional study. The FDA requested a randomized, double-blind, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug Presents Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159</link>
		<comments>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:50:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83159</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type I and type II diabetes, demonstrated that patients receiving avanafil achieved significant improvement in erectile function. The data reported that patients dosed with avanafil showed improvement in the percentage of successful intercourse attempts, regardless of diabetes classification (type I or II), duration of diabetes, or baseline ED severity. Further, successful intercourse was achieved in some patients within 15 minutes of taking avanafil. Moreover, some patients experienced successful intercourse more than six hours after dosing. On average, the patients who enrolled for the study were 58 years old and had a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Loss Narrowed Due To Lower Spend</title>
		<link>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947</link>
		<comments>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[OC]]></category>
		<category><![CDATA[Owens Corning]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80947</guid>
		<description><![CDATA[Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The company did not record any revenues during the quarter, similar to the prior-year quarter. The Zacks Consensus Estimate for the quarter was $1 million. Quarterly Details During the quarter, research and development (R&#38;D) expenses decreased 18.7% to $11.0 million. Moreover, general and administrative expenses amounted to $5.3 million, reflecting a decline of 21.4%. Vivus experienced reduced R&#38;D spends during the reported quarter, as both Qnexa and avanafil have completed their clinical studies and have been filed for regulatory approval. Pipeline Update In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug on Track</title>
		<link>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061</link>
		<comments>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:02:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77061</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) following bilateral, nerve-sparing, radical prostatectomy. The candidate met all the primary endpoints of the study, which included improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvement in the International Index of Erectile Function (IIEF). Additionally, the data showed that successful intercourse was achieved within 15 minutes of taking avanafil. On average, the patients who enrolled for the study were 58 years old, 19 months past their prostatectomy surgery dates and diagnosed with severe ED. The patients were given 100 mg or 200 mg of avanafil or placebo and were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus First Quarter 2011 Loss Narrower than Expected</title>
		<link>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458</link>
		<comments>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458#comments</comments>
		<pubDate>Fri, 06 May 2011 01:39:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73458</guid>
		<description><![CDATA[Vivus Inc.’s (VVUS) first quarter 2011 loss of 12 cents per share was narrower than the Zacks Consensus loss Estimate by 3 cents and the year-ago loss (from continuing operations) by 9 cents. The narrower loss in the reported quarter was attributable to a decline in operating costs. Vivus did not generate any revenues in the reported quarter as in the previous year. Operating expenses at Orexigen declined 35.6% to approximately $9.9 million. Research &#38; development (R&#38;D) expenses plummeted 56% to $4.5 million. General and administrative (G&#38;A) expenses increased marginally to $5.4 million in the reported quarter. The significant reduction in R&#38;D expenses was primarily attributable to the lower spend on clinical development of obesity candidate Qnexa and erectile dysfunction (ED) candidate, avanafil as both of them are nearing approval. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Qnexa Safety and Efficacy Information Published</title>
		<link>http://www.stockbloghub.com/2011/04/13/vvus-vivus-qnexa-safety-and-efficacy-information-published/71366</link>
		<comments>http://www.stockbloghub.com/2011/04/13/vvus-vivus-qnexa-safety-and-efficacy-information-published/71366#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:51:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71366</guid>
		<description><![CDATA[Recently, encouraging data were published on Vivus, Inc.’s (VVUS) weight loss candidate, Qnexa, in the journal, The Lancet. The 56-week late stage study (CONQUER: n=2,487) evaluated the safety and efficacy of Qnexa in overweight/obese patients suffering from high blood pressure, high cholesterol or type II diabetes. Data from the study, conducted across 93 sites in the US, revealed significant improvements in cardiovascular and metabolic disease risk factors in patients on being treated with Qnexa compared to those treated with a placebo. We note that Vivus is evaluating Qnexa as a potential treatment for weight loss, type II diabetes and obstructive sleep apnea. The candidate is in mid-stage development for type II diabetes and obstructive sleep apnea. We note that in October 2010, the US Food and Drug Administration (FDA) issued ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/vvus-vivus-qnexa-safety-and-efficacy-information-published/71366/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Qnexa Weight Loss Candidate Reports Encouraging Study Data</title>
		<link>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861</link>
		<comments>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:09:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70861</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently reported positive data from the SEQUEL study on its weight loss candidate, Qnexa. The 52-week SEQUEL study included 675 obese/overweight patients, who had two or more weight-related co-morbidities and an average baseline body mass index (BMI) of 36.1. SEQUEL is an extension study of patients who completed the 56-week CONQUER study. The study data demonstrated a reduction in blood pressure and the need to use antihypertensive medications, along with improved lipid levels. The improvement in lipid levels resulted from significant weight loss in patients treated with Qnexa for two years as compared to those in the placebo arm. We note that Vivus is evaluating Qnexa as a potential treatment for weight loss, type II diabetes and obstructive sleep apnea. The candidate is in mid-stage trials for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Gets US Food and Drug Administration Warning on Topamax</title>
		<link>http://www.stockbloghub.com/2011/03/27/jnj-johnson-and-johnson-gets-us-food-and-drug-administration-warning-on-topamax/68353</link>
		<comments>http://www.stockbloghub.com/2011/03/27/jnj-johnson-and-johnson-gets-us-food-and-drug-administration-warning-on-topamax/68353#comments</comments>
		<pubDate>Sun, 27 Mar 2011 13:50:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68353</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently issued a warning to pregnant women or women of child-bearing age who were being treated either with epilepsy drug Topamax (topiramate) or its generic equivalent. The regulatory body said that there was a risk of oral clefts among babies born to women who were on the drug during their pregnancy. Oral clefts can lead to problems of eating or talking and to ear infections in new born. The FDA intends to implement a stronger warning on the label of topiramate in order to caution patients about the risks associated with the drug. Johnson and Johnson (JNJ) markets Topamax for the treatment of certain types of seizures in epilepsy patients. The drug is also used to prevent migraine headaches. However, Topamax cannot be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/27/jnj-johnson-and-johnson-gets-us-food-and-drug-administration-warning-on-topamax/68353/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226</link>
		<comments>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226#comments</comments>
		<pubDate>Thu, 03 Feb 2011 17:21:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[COR]]></category>
		<category><![CDATA[Cortex Pharmaceuticals Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66226</guid>
		<description><![CDATA[Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and behavioral causes of obesity, has been co-developed with Japan’s Takeda. While issuing the CRL, dated January 31, 2011, the FDA stated that it is concerned about the long-term cardiovascular safety profile of the obesity candidate and has asked Orexigen to conduct an additional study. The request to conduct an additional study means further bad news for Orexigen as this will push up its research and development expenses. Orexigen intends to meet the FDA to discuss the issues raised in the CRL. The decision ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus Seeks EU Nod for Qnexa</title>
		<link>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722</link>
		<comments>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722#comments</comments>
		<pubDate>Tue, 28 Dec 2010 06:46:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63722</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric diet), including weight loss and maintenance of weight loss. Qnexa’s approval would be a major positive for Vivus. The obesity market represents huge commercial potential for Vivus. Obesity is a worldwide epidemic and is estimated to affect about 150 million adults in the EU. A smooth review process could result in Qnexa receiving EU approval in late 2011. Currently available treatments for obesity include orlistat, sold by Roche (RHHBY) as Xenical and by GlaxoSmithKline (GSK) as Alli (available over-the-counter). A commercially available prescription product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGP) Company News for October 29, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/11/01/agp-company-news-for-october-29-2010-corporate-summary/57087</link>
		<comments>http://www.stockbloghub.com/2010/11/01/agp-company-news-for-october-29-2010-corporate-summary/57087#comments</comments>
		<pubDate>Mon, 01 Nov 2010 18:01:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGP]]></category>
		<category><![CDATA[AMERIGROUP Corporation]]></category>
		<category><![CDATA[Calpine Corporation]]></category>
		<category><![CDATA[CEG]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Constellation Energy Group Inc]]></category>
		<category><![CDATA[CPN]]></category>
		<category><![CDATA[DTE]]></category>
		<category><![CDATA[DTE Energy Company]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Newell Rubbermaid Inc.]]></category>
		<category><![CDATA[NWL]]></category>
		<category><![CDATA[SNE]]></category>
		<category><![CDATA[Sony Corporation]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57087</guid>
		<description><![CDATA[• Microsoft (NASDAQ:MSFT) reported fiscal first quarter earnings of $0.62, above Zacks estimates of $0.55, on a 25.3% revenue jump to $16.2 billion, up from estimates of $15.7 billion • Newell Rubbermaid (NYSE:NWL) reported third quarter earnings $0.01 cents higher than Zacks estimates of $0.42, on in-line revenues of $1.5 billion • CIGNA&#8217;s (NYSE:CI) third-quarter results beat estimates by $0.04 at $1.10 on in-line revenues of $5.3 billion, up 16.6% YoY • Constellation Energy Group (NYSE:CEG) reported an earnings miss as third quarter results posted at $0.48, $0.16 under Zacks expectations on in-line revenues of $4 billion, down 1.5% • Aon Corp. (NYSE:AON) reported a third quarter earnings of $0.61, below Zacks estimates of $0.66, on in-line revenues of $1.8 billion, up 1.2% YoY • Merck (NYSE:MRK) reported better-than-expected earnings of $0.85, beating Zacks estimates of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/01/agp-company-news-for-october-29-2010-corporate-summary/57087/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Arena Pharmaceuticals is Denied FDA Approval for Obesity Candidate Drug</title>
		<link>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417</link>
		<comments>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:44:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56417</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company’s obesity candidate lorcaserin citing tumor-related safety concerns. The US regulatory authority issued a complete response letter (CRL) stating that the efficacy of the drug in non type II diabetes obese patients was found to be marginal. The FDA asked the company to submit the final study report of the BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in DiabetesMellitus) study which evaluated the efficacy of lorcaserin against placebo in obese and overweight patients suffering from type II diabetes. Arena intends to present top-line data from the study shortly and complete the study report by the end of this year. The FDA stated further that it may ask ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Removes Obesity Drug Meridia From Market</title>
		<link>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707</link>
		<comments>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707#comments</comments>
		<pubDate>Wed, 13 Oct 2010 02:14:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54707</guid>
		<description><![CDATA[Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs&#8217; decision was based on a request made by the US Food and Drug Administration (FDA). The FDA’s request was based on data from a post-marketing study (SCOUT &#8211; Sibutramine Cardiovascular OUTcome Trial), which showed that patients treated with Meridia experienced a 16% increase in the risk of cardiovascular events (non-fatal heart attack/stroke, the need to be resuscitated once the heart has stopped, and death) compared to placebo. Results also showed that the difference in weight loss between the Meridia and placebo arms was small. In mid-Sep 2010, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had conducted a meeting to review the drug. While 8 panelists were in favor of removing the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) FDA to Review Vivus Drug</title>
		<link>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446</link>
		<comments>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446#comments</comments>
		<pubDate>Thu, 15 Jul 2010 04:41:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43446</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently posted briefing documents on its website ahead of the review of Vivus’ (VVUS) obesity drug Qnexa by the FDA’s Endocrinologic &#38; Metabolic Drugs Advisory Committee. While the FDA said that all three doses of Qnexa were efficacious for weight loss, the agency has raised questions regarding certain safety issues. The FDA has highlighted five areas which will be discussed by the panel. These include psychiatric-related and cognitive-related adverse events, metabolic acidosis, cardiovascular events and the effect of the drug on pregnant women. We believe the main focus will be on increased adverse event reports of depression, anxiety, and sleep disorders and the potential clinical significance of the increase in heart rate. The advisory panel will be meeting on Jul 15 to discuss ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review</title>
		<link>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187</link>
		<comments>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32187</guid>
		<description><![CDATA[Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Obesity Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994</link>
		<comments>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994#comments</comments>
		<pubDate>Thu, 25 Feb 2010 23:18:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28994</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies. The decision is based on encouraging 52-week results on the combination treatment from a blinded, placebo-controlled phase II extension study in which the combination succeeded in achieving the key target of sustained and robust weight loss. Results showed that patients who continued treatment with pramlintide/metreleptin for 52 weeks experienced sustained weight loss, while those on placebo regained almost all of their weight. The combination treatment was found to be most effective in patients with a body mass index (BMI) less than 35 kg/m2. The combination treatment was generally well tolerated, with nausea and injection-site-adverse events being the most common side effects ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck &amp; Co Ends Deal with Arena Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734</link>
		<comments>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:11:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23734</guid>
		<description><![CDATA[Merck &#38; Co (MRK) recently informed its partner Arena Pharmaceuticals (ARNA) that it was pulling out of a collaboration agreement pertaining to the development of an atherosclerosis drug. The decision by Merck to discontinue the development of the candidate, MK-1903, a niacin receptor agonist for treating atherosclerosis, followed disappointing results from a recently completed mid-stage study. The randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability and potential efficacy in patients with dyslipidemia. The study did not meet the primary objective for efficacy. The drug failed to significantly raise patients&#8217; levels of good cholesterol (HDL) compared to a placebo. However, Merck’s decision to pull out of the deal was not related to any safety concerns pertaining to the drug. Atherosclerosis is the thickening of the artery walls which often leads to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Amylin Pharmaceuticals Strikes First on Obesity</title>
		<link>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415</link>
		<comments>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:30:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19415</guid>
		<description><![CDATA[Almost all of the news in the obesity race has been made recently by three small biotech companies &#8212; Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race. Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesity. As part of the transaction, Amylin will receive a one-time up-front payment of $75 million from Takeda. Amylin is also eligible to receive additional payments based on development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

